GU Cancers Symposium

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

“Neoadjuvant and adjuvant EV/pembro significantly improved event-free survival, overall survival, and path CR rate vs neoadjuvant gem/cis in patients with muscle-invasive bladder cancer who are eligible for cisplatin-based chemotherapy and radical cystectomy," said Matthew D. Galsky, MD.

Pooja Ghatalia, MD, shares data from an integrated analysis of the RETAIN trials in muscle-invasive bladder cancer.

“Biochemical responses were seen at all dose levels, with an overall PSA50 response of 62% and a PSA90 response of 40%," according to Fred Saad, CQ, MD, FRCS, FCAHS.

Karim Fizazi, MD, PhD, reported that the 9-year prostate cancer-specific survival rate was 90% (95% CI, 86-94) in patients receiving cabazitaxel vs 89% (95% CI, 84-93) in patients not receiving cabazitaxel.

"Capivasertib in combination with abiraterone represents a potential first-in-class targeted treatment for patients with this now PTEN-defined metastatic APMN,” said Daniel J. George, MD.

Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue.

Enrique Gallardo, MD, discusses the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in patients with metastatic castration-resistant prostate cancer.

"Enzalutamide plus radium-223 is an option in first-line treatment for mCRPC patients with bone metastases," said Enrique Gallardo, MD.

Median OS was 28 months (95% CI, 13-NR) in arm 1, 37 months (95% CI, 26-NR) in arm 2, and 68 months (95% CI, 38-NR) in arm 3.

Robert S. Svatek, MD, MSCI, highlights some of the greatest unmet needs in the non–muscle invasive bladder cancer space.

Leslie K. Ballas, MD, discusses the background and design for the phase 2 BRIGHT trial, evaluating a risk-adapted bladder preservation strategy in MIBC.

Take a look into the top data set to be presented at this year's ASCO GU Cancers Symposium in San Francisco, California.

The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.

“There are plans now to continue the dose optimization to identify the exact dose for a further expansion,” says Gopa Iyer, MD.

“We found that the median rPFS with the combo of mevrometostat plus enzalutamide was 14.3 months, which compared favorably with what we saw with the enzalutamide arm, where the median was only 6.2 months,” says Michael Schweizer, MD.

“We hypothesized based on prior work that specifically men with low-volume disease, if they inherit this hyperactive form of HSD3B1, they'll have shorter overall survival. It turns out that that's true,” says Nima Sharifi, MD.

The pCR rate was 33% with APL-1202 plus tislelizumab compared with 26% with tislelizumab alone.

“We took the urine from those patients, and we tested to see if we can predict their gemcitabine metabolism capability. We were able to predict it pretty accurately,” says Laura Bukavina, MD, MPH.

"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.

“To add to the complexity is the issue of intratumoral heterogeneity, where some clones may develop these resistance mechanisms and lose response over time or become resistant, while other clones will continue to respond,” says Kate H. Gessner, MD, PhD.

“It shows the significant poor outcomes in this population with our standard therapies and the need to improve upon that by developing novel treatments,” says Darren R. Feldman, MD.

Hear insights from experts on key trial data presented at ASCO GU 2025.

“Among active surveillance patients, 82% are metastases-free, and 60% were metastases-free and had an intact, unradiated bladder,” said Pooja Ghatalia, MD.

However, the triplet regimen did not lead to an improvement in overall survival.

“Taken altogether, the study remains positive for PFS, but not for overall survival,” says Laurence Albiges, MD, PhD.

“Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.

"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP.

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD.